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Context: Among cytokines, fibroblast growth factor 21 (FGF21), adiponectin (Adn), and irisin have
been considered potential biomarkers for insulin sensitivity (IS).
Objective: We evaluated whether serum FGF21, Adn, and irisin associate with markers of IS and
serum lipids in 12-year-old children.
Design, Participants, and Main Outcome Measures: This cohort study included 192 12-year-old
children (109 girls). Seventy-eight of them had been born appropriate for gestational age (AGA), 70
small for gestational age (SGA), and 44 from preeclamptic pregnancies (PREs) as AGA. Fasting serum
FGF21, Adn, irisin, lipids, inflammatorymarkers, and ISmarkers weremeasured. Quantitative insulin
sensitivity check index (QUICKI) was calculated.
Results: The means of serum FGF21, high molecular weight (HMW) Adn, and irisin did not differ
between the sexes or between the SGA, AGA, and PRE children. In the whole study population, FGF21
associated positively with irisin and uric acid and negatively with leptin and high-density lipoprotein
cholesterol (HDL-C). HMW Adn associated positively with total Adn, HDL-C, leptin, and SHBG. Apart
fromFGF21, irisinassociatedpositivelywith insulin, high-sensitivityC-reactiveprotein,g-glutamyltransferase,
and triglycerides, and negatively with QUICKI, SHBG, and IGF binding protein-1. In multivariate
regression analyses, irisin predicted lower IS and HMWAdn predicted higher HDL-C body mass index-
independently, whereas FGF21 had no independent contribution to IS or lipid variables.
Conclusion: In 12-year-old children, serum irisin was associated with markers reflecting reduced IS.
HMW Adn predicted HDL-C, whereas FGF21 did not contribute to IS or lipid parameters in multi-
variate regression analyses.
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Adipose tissue (AT) and skeletal muscles secrete cytokines, specifically adipokines and
myokines that interact with each other. These cytokines are able to modulate energy ho-
meostasis, adipogenesis, inflammation, endothelial function, glucose metabolism, and in-
sulin sensitivity (IS), and thus body composition [1, 2]. Metabolic stress in white AT leads to
dysregulated cytokine synthesis and secretion, which may contribute to obesity-associated
metabolic, inflammatory, and cardiovascular comorbidities [1].
Fibroblast growth factor 21 (FGF21) is a cytokine produced primarily in the liver but also
in other tissues such as skeletalmuscle, white and brownAT, and pancreas [3, 4]. It belongs to
the FGF superfamily, but unlike most of the FGFs it acts mainly in an endocrine manner [3].
To bind to its receptors and initiate signaling, FGF21 needs a cofactor, b-Klotho, expressed
in a few metabolic tissues [3, 4]. According to animal studies, FGF21 has beneficial effects on
IS, glucose, and lipid metabolism and energy homeostasis [3], and it regulates thermogenesis
[5]. In humans, elevated FGF21 levels have been reported in insulin-resistant states and to
independently predict metabolic syndrome and type 2 diabetes [6–8]. Furthermore,
FGF21 has been associated with obesity already in childhood [9], but this finding is not
consistent [10].
Adipocyte-produced adiponectin (Adn) [1, 11] mediates the beneficial effects of FGF21 on IS
and energy metabolism in the skeletal muscle and liver [3]. Furthermore, Adn itself has anti-
inflammatory, insulin sensitizing, energy expenditure increasing, and antiapoptotic properties
[1, 11]. In clinical studies, circulating Adn correlated negatively with insulin resistance, visceral
fat amount, type 2 diabetes, serum lipid levels, and blood pressure (BP) [1, 11]. Its low circulating
concentrations predict type 2 diabetes, whereas its association with cardiovascular disease
(CVD) is obscure [1]. The serum concentration of high molecular weight (HMW) Adn has been
shown to correlate better with systemic IS than that of the lowmolecular weight isoform [1, 11].
The myokine irisin is a cleavage product of the fibronectin type III domain-containing
protein 5 (FNDC5). Irisin is secretedmainly bymuscle, but AT and other tissues secrete small
amounts of it. In mice, irisin increases energy expenditure by stimulating the browning of
white AT, and it improves glucose homeostasis and lipid profile [12]. In adults and children,
elevated irisin concentrations have been observed in insulin resistance and obesity [12–16],
but they decrease in type 2 diabetes [17]. However, the results in human studies have been
inconsistent [12].
The aim of the current study was to determine whether serum FGF21, HMW Adn, and
irisin concentrations associate with cardiometabolic risk markers, such as reduced IS or
altered lipid profiles in 12-year-old children. Furthermore, we wanted to investigate whether
they associate with low birth weight or exposure to maternal preeclampsia, which are
considered to independently predispose to later metabolic disorders and CVD [18–20]. Fi-
nally, we sought to compare FGF21, HMW Adn, and irisin with other insulin resistance–
related parameters in terms of detecting reduced IS, unfavorable lipid profiles, and elevated
24-hour ambulatory BP.
1. Materials and Methods
A. Definitions
Preeclampsia was defined as the development of hypertension and proteinuria (.300 mg of
urinary protein in 24 hours) after 20 weeks’ gestation [21]. Hypertension was defined as
BP .140/90 mm Hg or a rise of $30/15 mm Hg from the baseline level, confirmed by two
measurements$6 hours apart. Full-term indicates babies born at or after week 37 and before
the 42nd week of gestation, and preterm indicates babies born before the 37th week of
gestation (calculated from the beginning of the last menstruation). Small for gestational age
(SGA) was defined as birth weight and/or length.2 SD scores below the respective mean for
the gestational age and sex. Appropriate for gestational age (AGA) was defined as birth
weight and birth length equal to or above22 SD scores and equal to or below +2 SD scores of
the respective means for gestational age and sex [22].
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B. Subjects
The study population consisted of a cohort of 192 12-year-old children who originally were
recruited to a study investigating the metabolic consequences of either being born SGA or being
born after a preeclamptic pregnancy (PRE).Of this cohort 109were girls, 70were bornSGA, and
44 were born after a PRE as AGA. Themedian of the gestational ages was 38.0 weeks (range 28
to 42 weeks). Extremely preterm children born before gestational week 28 were excluded from
the study. None of the participating children was exposed to exogenous glucocorticoids pre-
natally. All childrenwere born atKuopioUniversityHospital during a 22-month period between
1984 and 1986. The study protocol was approved by the Research Ethics Committee of Kuopio
University Hospital. Informed written consent was obtained from the child and the parents.
C. Methods
Perinatal data, anthropometric measures, and ambulatory BP values at 12 years age have
been described previously for the SGA [23, 24] and PRE children [25, 26]. Pubertal devel-
opment was classified as Tanner stages according to breast development (B) in girls and
genital development (G) in boys. Body mass index (BMI; calculated as weight in kilograms
divided by height in meters squared) and sex- and adult age–adjusted BMI (BMIadj; cor-
responding to the BMI values at the age of 18 years) [27] were calculated. Waist-to-height
ratio (WHtR) was calculated by dividing waist circumference (in centimeters) by height (in
centimeters). Perinatal characteristics, anthropometricmeasures, and pubertal development
at the age of 12 years in the whole study population are presented in Table 1.
C-1. Laboratory methods
Blood samples were taken in the morning, between 0900 and 1000 hours, after an overnight
fast. An IV cannula was placed in the antecubital vein for blood sampling. After the child had
rested for 1 hour in a recumbent position, blood samples were drawn through the cannula.
Serum specimens were immediately frozen and stored at 270°C until analyzed.
Serum irisin concentrations were measured with ELISA kits (#EK-067-52, Phoenix Phar-
maceuticals Inc, Burlingame, CA) [28]. The detection range of the assay was 0.066 to 1024 ng/
mL, and the intra-assay and interassay coefficients of variation (CVs) were ,6% and ,10%,
respectively. Serum FGF21 concentrations were measured with a highly specific ELISA kit
(BioVendor, Brno, Czech Republic) [29], and the respective CVs were 2.0% and 3.3%. Serum
total Adn and HMW Adn were measured by ELISA (Quantikine DRP300, R&D Systems, Inc.,
Minneapolis, MN; EZH MWA-64K, Merck Millipore, Darmstadt, Germany) [30, 31]; the intra-
assay and interassay CVs for total Adn were,4.7% and,6.9%, and those for HMWAdn were
,8.8% and 6.1%. Serum insulin concentrations were determined by RIA (Phadeseph Insulin
RIA, Pharmacia & Upjohn Diagnostics AB, Uppsala, Sweden). The intra-assay and interassay
CVs for insulin were 5.3% and 7.6%, respectively. Blood glucose concentrations were analyzed
by a glucose oxidase method (Enzyme Electrode, Nova Biomedical, Waltham, MA), and the
respective CVs were 3% and 5%. Serum high-density lipoprotein cholesterol (HDL-C) and
triglycerides (TGs) were measured enzymatically by an automatic photometric method (Roche
Molecular Biochemicals, Mannheim, Germany), and the interassay CVs were 4.1% at 0.84 mM
and 3.8% at 1.69 mM, and 3.2% at 1.23 mM and 1.6% at 2.45 mM, respectively. Low-density
lipoprotein cholesterol (LDL-C) concentrations were calculated by the Friedewald-Fredrickson
formula [LDL-C = total cholesterol – (HDL-C + TG/2.2)]. Serum IGF-1 and IGF binding
protein-1 (IGFBP-1) concentrations were analyzed by ELISA (DSL-10-5600 Active IGF-I
ELISA; DSL-10-7800 Active Total IGFBP-1 ELISA, both from Diagnostic Systems Labo-
ratories, Inc., Webster, TX) [32, 33]. The intra-assay CV for IGF-1 was 6.5%, and the
interassay CV was 6.4%, as reported by the manufacturer; for IGFBP-1 the respective CVs
were 2.5% and 6.8%. Serum SHBG was measured by the AutoDELFIA SHBG time-resolved
fluoroimmunoassay method (Perkin Elmer Life Sciences Wallac, Turku, Finland). The intra-
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assay and interassay CVs were 4.0% and 2.6%, respectively. Serum leptin concentrations
were analyzed by ELISA (Quantikine DLP00, R&DSystems, Inc.) [34], with its intra-assay
and interassay CVs 3.2% and 3.5%. Serum high-sensitivity C-reactive protein (hs-CRP)
concentrations were determined by a photometric immunoturbidimetric method (Konelab
20XT Clinical Chemistry Analyzer, Konelab, Thermo Fisher Scientific, Vantaa, Finland), and
the interassay CVs were 5.0% at 0.78 mg/L and 2.3% at 2.55 mg/L. Serum g-glutamyl-
transferase (GGT) and uric acid were measured by enzymatic photometric tests (Konelab 20
XT, Clinical Chemistry Analyzer, Thermo Fisher Scientific). The intra-assay CV for GGT was
3.3%, and the interassay CV was,2.4%; for uric acid the respective CVs were 4.0% and 2.9%.
Quantitative insulin sensitivity check index (QUICKI) was calculated as 1/[log (fasting
insulin, mU/mL) + log (fasting glucose, mg/dL)] [35].
Table 1. Anthropometric Characteristics and Biochemical Parameters for the Whole Study Population
and for Girls and Boys Separately
Variable All (n = 192) Girls (n = 109) Boys (n = 83) Pa Pb
At birth
Gestational age, wkc 37.5 (37.0, 38.0) 37.9 (37.3, 38.6) 37.0 (36.3, 37.8) 0.069
Weight, g 2769 (2662, 2877) 2736 (2586, 2886) 2813 (2659, 2967) 0.482
Weight, SDS 21.14 (21.33, 20.95) 21.27 (21.55, 21.00) 20.97 (21.23, 20.71) 0.111
Length, cm 47.3 (46.7, 47.8) 47.0 (46.3, 47.8) 47.6 (46.8, 48.4) 0.260
Length, SDS 20.88 (21.09, 20.67) 21.02 (21.31, 20.74) 20.69 (21.00, 20.38) 0.117
At the age of 12 y
Age, yrc 12.25 (12.23, 12.27) 12.25 (12.22, 12.29) 12.25 (12.21, 12.28) 0.868
Weight, kgc 43.00 (41.60, 44.44) 43.14 (41.26, 45.09) 42.81 (40.70, 45.03) 0.816
BMIadj, kg/m2c 21.15 (20.63, 21.68) 20.65 (20.02, 21.31) 21.81 (20.96, 22.70) 0.028 0.001d
Height, cm 153.2 (152.1, 154.2) 153.9 (152.4, 155.4) 152.2 (150.6, 153.8) 0.119
Height, SDS 0.26 (0.12, 0.41) 0.16 (-0.04, 0.36) 0.40 (0.18, 0.61) 0.116
WHtR 0.43 (0.42, 0.44) 0.42 (0.41, 0.43) 0.44 (0.43, 0.45) 0.013 0.012d
Pubertal development,e
early/late stage, n
107/85 38/71 69/14 <0.001f
Pubertal development <0.001f
Tanner B/G stage 1, n 40 14 26
Tanner B/G stage 2, n 67 24 43
Tanner B/G stage 3, n 50 38 12
Tanner B/G stage 4, n 27 25 2
Tanner B/G stage, 5 n 8 8 0
S-FGF-21, ng/L c 95.7 (82.4, 111.2) 109.0 (89.2, 133.1) 80.8 (64.4, 101.3) 0.051 0.253
S-Adn, mg/Lc 9.4 (8.7, 10.2) 9.8 (8.9, 10.8) 8.9 (7.7, 10.2) 0.375 0.150
S-HMW Adn, mg/Lc 4.5 (4.1, 4.9) 4.5 (4.1, 5.0) 4.4 (3.7, 5.1) 1.000 0.612
S-Irisin, mg/Lc 135.4 (128.0, 143.3) 132.5 (123.6, 142.0) 139.4 (126.9, 153.1) 0.378 0.458
S-Insulin, mU/Lc 9.4 (8.9, 9.9) 10.3 (9.5, 11.1) 8.3 (7.7, 9.0) <0.001 <0.001
B-Glucose, mmol/L 4.3 (4.3, 4.4) 4.3 (4.2, 4.3) 4.4 (4.3, 4.5) 0.009 0.025
QUICKI 0.351 (0.348, 0.354) 0.347 (0.342, 0.352) 0.356 (0.351, 0.361) 0.007 0.005
S-IGFBP-1, mg/Lc 56.4 (51.8, 61.4) 51.6 (45.9, 58.0) 63.4 (56.0, 71.7) 0.017 0.007
S-IGF-1, mg/L 314.3 (296.3, 332.4) 360.5 (338.2, 382.7) 253.8 (228.9, 278.6) <0.001 <0.001
S-SHBG, nmol/L 73.5 (68.9, 78.2) 69.6 (63.7, 75.5) 78.7 (71.3, 86.2) 0.060 0.032
S-Leptin, mg/Lc 8.6 (7.3, 10.1) 11.2 (9.2, 13.6) 6.1 (4.7, 7.8) <0.001 <0.001
S-GGT, U/Lc 15.9 (15.5, 16.3) (n = 191) 15.4 (15.0, 15.8) (n = 108) 16.6 (15.9, 17.3) 0.004 0.082
S-Uric acid, mmol/L 276.7 (268.0, 285.4) (n = 191) 274.1 (262.7, 285.5) (n = 108) 280.1 (266.5, 293.7) 0.503 0.027
S-Triglycerides, mmol/Lc 0.85 (0.06, 0.90) 0.90 (0.84, 0.98) 0.78 (0.72, 0.85) 0.011 0.002
S-HDL cholesterol, mmol/L 1.32 (1.28, 1.36) 1.30 (1.25, 1.35) 1.35 (1.29, 1.41) 0.223 0.904
S-LDL cholesterol, mmol/L 2.76 (2.66, 2.86) 2.79 (2.67, 2.91) 2.72 (2.56, 2.89) 0.410 0.054
S-hs-CRP, mg/Lc 0.25 (0.20, 0.30) (n = 191) 0.21 (0.17, 0.27) (n = 108) 0.30 (0.22, 0.41) (n = 83) 0.126 0.376
24-h systolic BP, mm Hg 117 (116, 118) (n = 180) 116 (115, 118) (n = 100) 117 (116, 119) (n = 100) 0.354g 0.272h
24-h diastolic BP, mm Hg 68 (68, 69) (n = 180) 68 (67, 69) (n = 100) 69 (68, 70) (n =80) 0.380g 0.239h
The means (95% CIs) are presented. Significant P - values are bold.
Abbreviations: B, blood; S, serum; SDS, SD score.
aIndependent-samples t test for the differences between the girls and boys.
bComparison by ANCOVA adjusted for BMIadj and pubertal developmental stage (G/B 1 to 5).
cGeometric means (95% CIs) are presented for the variables with skew distributions.
dComparison by ANCOVA adjusted for pubertal developmental stage (G/B 1 to 5).
eEarly stage of puberty, breast or genital scores 1 to 2; late stage of puberty, breast or genital scores 3 to 5.
fChi-square test for differences between girls and boys.
gComparison by ANCOVA adjusted for BMIadj and height (SDS).
hComparison by ANCOVA adjusted for BMIadj, pubertal developmental stage (G/B 1 to 5) and height (SDS).
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D. Statistical Analyses
Datawere analyzed with the statistical program SPSS forMacintosh, version 24.0 (SPSS, IBM
Corp., Armonk, NY). All continuous variables were examined for normality with the
Kolmogorov-Smirnov test. Skewed datawere either logarithmically or square root transformed
before testing. Independent samples t test, univariate ANOVA, or analysis of covariance
(ANCOVA) were used for comparisons between groups. Sidak correction was used for post hoc
tests. Linear regression analyses were used for estimating the associations between FGF21,
HMW Adn, and irisin concentrations with cardiometabolic variables; standardized b-values
are reported in these analyses. Multivariate regression analyses were performed to evaluate
the independent contributions of measured cytokines, IS markers, and BMIadj to IS, lipid
variables, and ambulatory BP values. P , 0.05 was accepted as significant in all analyses.
2. Results
A. Sex-Specific Anthropometric and Biochemical Characteristics of the Study Population
At the age of 12 years, the boys had higherWHtR and BMIadj than the girls (Table 1). Pubertal
development was more advanced in the girls than boys: 87% of girls and 69% of boys had
pubertal signs (Tanner stage B/G$2) (Table 1). The SGA-born childrenwere shorter compared
with the AGA-born and PRE children in terms of height SD scores (SGA vs AGA 20.19 and
0.63, P , 0.001; and SGA vs PRE 20.19 and 0.33, P = 0.016, respectively, by Sidak-adjusted
ANOVA) and leaner than the AGA-born childrenmeasured by BMIadj (20.44 and 22.14 kg/m2,
P = 0.020, by Sidak-adjusted ANOVA). Pubertal development did not differ between the SGA,
AGA, and PRE subgroups or between the preterm and full-term subjects (data not shown).
At the age of 12 years, the mean concentrations of serum FGF21 tended to be higher in the
girls compared with the boys (P = 0.051). However, further adjustment for pubertal de-
velopmental stage andBMIadj attenuated the significance (Table 1). Serum total andHMWAdn
and irisin concentrations did not differ between the sexes (Table 1). The girls had significantly
higher serum IGF-1, insulin, leptin, and TG concentrations and lower QUICKI, blood glucose,
and serum IGFBP-1 concentrations comparedwith the boys (Table 1). The sex difference inGGT
was attenuated after adjustment for pubertal developmental stage and BMIadj (Table 1). SHBG
and uric acid were significantly lower in the girls, when adjusted for pubertal developmental
stage and BMIadj (Table 1). Pubertal developmental stage had no effect on serum FGF21 or
irisin concentrations, when the sexes were analyzed separately (girls, P = 0.934 for FGF21 and
P = 0.305 for irisin; boys, P = 0.628 for FGF21 and P = 0.226 for irisin, by Sidak-adjusted
ANOVA), in thewhole study population (P= 0.447 andP= 0.176, respectively, by Sidak-adjusted
ANOVA), or between the sexes within the same Tanner stage (data not shown). However, the
boys had lower HMW Adn concentrations in Tanner stage G3 than in stages G1 or G2 (G3
1.67 mg/L vs G1 2.33 mg/L, P = 0.031; and G3 1.67 mg/L vs G2 2.29 mg/L, P = 0.029, by Sidak-
adjusted ANOVA) and lower than the girls in Tanner stage B3 (1.67 vs 2.18 mg/L, P = 0.021,
respectively, by independent samples t test). The concentrations of serum FGF21, HMW Adn,
irisin, GGT, IGF-1, IS markers (QUICKI, IGFBP-1, SHBG), or lipids did not differ between the
AGA, SGA, and PRE subgroups or between the preterm and full-term subjects (data not shown).
B. Factors Associated With Serum FGF21, HMW Adn, and Irisin Concentrations
In the whole study population, FGF21 had a positive association with irisin and uric acid
and a negative association with HDL-C in linear regression analyses adjusted for sex and
pubertal developmental stage, even after further adjustment for BMIadj (Table 2). Fur-
thermore, when adjusted for BMIadj, a negative association between FGF21 and leptin
turned significant (Table 2). The positive association between FGF21 and irisin remained
significant in the boys (n = 83, b = 0.417, P , 0.001 in analysis adjusted for both pubertal
developmental stage and BMIadj). Moreover, FGF21 had a positive association with IGF-1 in
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boys (n = 83, b = 0.349, P = 0.014) in BMIadj-adjusted analyses. FGF21 concentrations had no
association with birth weight or preeclamptic history in linear regression analyses (Table 1).
We found positive associations between serum HMW Adn and QUICKI, IGFBP-1, SHBG,
total Adn, andHDL-C and negative associations with serumGGT, BMIadj, andWHtR (linear
regression analyses adjusted for sex and pubertal developmental stage) (Table 2). The as-
sociations between HMW Adn and QUICKI, IGFBP-1, and GGT were attenuated after
BMIadj adjustment (Table 2). In contrast, the positive association with leptin turned sig-
nificant in BMIadj-adjusted analyses (Table 2). The strong positive association between
HMW Adn and HDL-C remained in the boys (n = 83, b = 5.990, P , 0.001), whereas it was
attenuated in the girls after BMIadj adjustment (n = 109, b = 1.942, P = 0.056). In boys, HMW
Adn had a negative association with TG and a positive association with leptin in BMIadj-
adjusted analyses (n = 83; b = 20.315, P = 0.011; b = 0.532, P = 0.003, respectively). Fur-
thermore, in boys BMIadj-dependent associations were found between HMW Adn and
IGFBP-1, IGF-1, and SHBG (n = 83; b = 0.241, P = 0.046; b =20.292, P = 0.046; b = 0.273, P =
0.027, respectively). In girls, HWMAdn associated positively with SHBG in linear regression
analysis adjusted for pubertal developmental stage (n = 109, b = 0.220,P = 0.021). Finally, low
birth weight (SD score) predicted independently low HMW Adn after adjustment for sex,
pubertal developmental stage, and BMIadj in linear regression analysis (Table 2).
In the whole study population, serum irisin had positive associations with serum FGF21,
insulin, GGT, hs-CRP, and TG and negative associations with QUICKI, IGFBP-1, and SHBG
(linear regression analyses adjusted for sex and pubertal developmental stage) (Table 2). All
these associations remained significant after further adjustment for BMIadj. In subgroup
analyses, the associations between irisin and insulin, and irisin and QUICKI remained
significant even after BMIadj adjustment in both girls (n = 109; b = 0.325, P = 0.002; b =
20.272, P = 0.007, respectively) and boys (n = 83; b = 0.370, P = 0.018; b =20.302, P = 0.041,
respectively). In girls, positive associations between serum irisin andGGT (n = 108, b = 0.256,
P = 0.025), TGs (n = 109, b = 0.210, P = 0.020), and hs-CRP (n = 108, b = 0.257, P = 0.018) were
found even after adjustments for BMIadj. In contrast, in boys BMIadj-independent associ-
ations were found between serum irisin and FGF21 (n = 83, b = 0.482, P , 0.001), IGFBP-1
(n = 83, b =20.312, P = 0.035), SHBG (n = 83, b =20.372,P = 0.023), and 24-hour diastolic BP
(n = 80, b = 0.283, P = 0.021). In linear regression analyses, birth weight or preeclamptic
history had no association with irisin concentrations (Table 2).
Associations of serum FGF21, HMW Adn, and irisin with metabolic and anthropometric
variables in the SGA, AGA, and PRE subgroups are shown in an online repository [36]. Some
of the unfavorable associations tended to be stronger in the SGA thanAGA or PRE subgroups.
C. FGF21, HMW Adn, and Irisin as Markers of Reduced IS and Unfavorable Lipid Profile
Multivariate linear regression analyses were performed to estimate independent contri-
butions of FGF21, HMW Adn, irisin, and other insulin resistance–related markers to car-
diometabolic risk factors (estimated by QUICKI, 24-hour ambulatory systolic BP, and serum
TG and HDL-C concentrations). In analyses adjusted simultaneously for both sex and
pubertal stage, higher serum irisin and lower IGFBP-1 predicted lower IS independently
of BMIadj. In addition, low birth weight had an independent contribution to low IS (Table 3).
Higher serum HMWAdn was a positive predictor for HDL-C (Table 3). Low birth weight (SD
score), maternal preeclampsia, and lower IGFBP-1 associated independently with higher
24-hour ambulatory systolic BP mean (Table 3), whereas FGF21, HMWAdn, or irisin had no
independent contribution. The contribution of BMIadj was significant in all analyses with the
exception of TG levels (Table 3).
3. Discussion
The current study revealed that serum irisin could predict reduced IS independently of BMIadj.
In linear regression analyses, irisin was associated independently of BMIadj, sex, and pubertal
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developmental stage with several markers reflecting reduced IS (low QUICKI, IGFBP-1, and
SHBG). SerumHMWAdnwas a positive predictor for HDL-C, whereas its associations with IS
markers were BMIadj dependent. FGF21 had no independent effect on IS or lipid variables in
multivariate regression analyses. Low birthweight was an independent contributor to lower IS
and higher 24-hour ambulatory systolic BP values. Minor sex differences in the associations
were found. Moreover, some of the unfavorable associations tended to be stronger in the
children born SGA than in those born AGA or from preeclamptic pregnancies.
FGF21 inhibits lipolysis, induces browning of white AT, promotes pancreatic b-cell
function and survival, and protects against insulin resistance and obesity [3–5]. In clinical
studies, recombinant FGF21 has been shown to improve dyslipidemia, decrease insulin
levels, and lower body weight, whereas no glucose-lowering effects have been found [4].
However, obesity has been proposed to be an FGF21-resistant state [6] and FGF21 to be a
marker of adverse metabolic profiles in adults [8, 37]. Studies conducted in children or
adolescents are scarce, with inconsistent results. Positive associations have been reported
between FGF21 and BMI [9] or weight SD score [38]; however, the majority of the study
subjects in these reports have been overweight or obese. Contrary to these studies, Li et al.
[10] demonstrated recently in a large Chinese study that serum FGF21 was negatively
associated with obesity. Finally, Hanks et al. [39] reported no association of FGF21 with
weight parameters, which is consistent with our results based on mainly normal-weight
12-year-old children. Furthermore, the reported associations of FGF21 with insulin levels or
insulin resistance indices have been either positive [38], negative [10], or insignificant [9], the
latest in accordance with our findings. In our study, serum FGF21 associated negatively with
HDL-C and leptin in BMIadj-adjusted linear regression analyses. Previously reported cor-
relations of FGF21 with HDL-C have been positive [10], and those with leptin have been
inconsistent [9, 10]. In normoglycemic and type 2 diabetic adults, high serum FGF21 levels
were associated with an adverse lipid profile [6, 7]. However, null results have also been
reported in these association studies [8]. Furthermore, we found no association of FGF21with
Adn, although FGF21 increases Adn expression and its serum levels [3]. In line with our
findings, a study of overweight and obese children and adolescents found no association
between FGF21 and Adn [38], whereas Li et al. [10] reported a positive correlation between
these parameters. The discrepancies may be explained by differences in the sample sizes and
metabolic status of the participants or by variable controlling of confounding factors.
In addition to adipocytes, Adn is expressed in many other cell types, including skeletal and
cardiac myocytes and epithelial cells [11]. It not only regulates IS and energy homeostasis [1]
but also improves lipid profile [11]. In adults, serum Adn levels decrease in obesity, type 2
diabetes, metabolic syndrome, and CVD [1]. HMW multimer is considered the most active
Adn isoform [1, 11], and downregulation of HMWAdn has been shown to reflect vascular and
metabolic abnormalities better than that of total Adn [40, 41]. Furthermore, low HMW Adn
levels have been linked to obesity, especially abdominal obesity, already in childhood [40, 42,
43] and adolescence [41]. However, in accordance with our results, the association between
HMW Adn and insulin resistance can be explained by adiposity [42]. In line with our results,
BMI-independent positive associations between HMW or total Adn and HDL-C have been
reported in adolescents [44] and adults [37]. Furthermore, in our SGA subgroup, the
BMI-independent negative association of HMW Adn with TG was significant similarly to
several other studies with children and adolescents [40, 41, 44].
Irisin was discovered primarily as an exercise-regulated myokine that induces browning of
white AT [12, 45]. Its physiologic significance in humans is debated, and the reported findings
are controversial. Furthermore, in humans, circulating irisin concentrations have been ob-
served to differ greatly, and the validity of different assays has been questioned [12]. In some
human studies with few participants, FNDC5 and irisin levels have been reported to increase
after exercise, but this finding has not been confirmed by others [reviewed in 12]. Although in
subjects with obesity FNDC5 expression in adipocytes and consequently irisin secretion is
lower [12, 17], the concentrations of serum irisin may be similar or higher than in normal-
weight subjects because of increased fatmass [12]. AThas been hypothesized to secrete irisin in
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obesity and insulin resistance in an effort to increase IS [13, 46]. Consequently, serum irisin
concentrations have been found to associate positively with BMI, whole body mass, fat mass
and waist-to-hip ratio [47, 48], insulin resistance indices [13, 14, 16, 47], and the risk of
metabolic syndrome [13]. However, no [15, 16] or negative [17] correlations between irisin and
weight parameters and insulin resistance indices [49] have been reported.We found a negative
BMIadj-independent association between irisin and QUICKI. Conflicting results have been
reported with regard to serum irisin levels and lipid profile. We found a positive association
between irisin andTG, supporting previous data in adults [13, 46] andKorean adolescents [48].
Also, a negative correlation between HDL-C and irisin has been found [13, 16], whereas others
have reported no correlation [17, 47], in accordance with our findings. In contrast, two large
studies demonstrated irisin to associate with a favorable lipid profile [49, 50]. The
Table 3. Biochemical and Anthropometric Factors Predicting Cardiovascular RiskMarkers in 12-Year-
Old Children
Dependent Variable Covariates Independent Variable r2 b P n
QUICKI Sex, pubertal stage FGF21 0.504 20.018 0.753 191
HMW Adn 20.020 0.727
Irisin 20.125 0.030
IGFBP-1 0.457 <0.001
SHBG 0.102 0.169
GGT 20.076 0.192
Uric acid 0.019 0.152
BMIadj 20.183 0.022
Preeclampsia 0.001 0.597
Birth weight, SDS 0.002 0.026
HDL-C Sex, pubertal stage FGF21 0.288 20.122 0.073 191
HMW Adn 0.343 <0.001
Irisin 20.018 0.711
IGFBP-1 20.002 0.716
SHBG 0.004 0.471
GGT 0.145 0.217
Uric acid 20.068 0.481
BMIadj 20.065 0.022
Preeclampsia 0.008 0.651
Birth weight, SDS 0.002 0.716
Triglycerides Sex, pubertal stage FGF21 0.183 0.085 0.243 191
HMW Adn 20.030 0.683
Irisin 0.066 0.385
IGFBP-1 20.009 0.232
SHBG 20.015 0.079
GGT 0.151 0.403
Uric acid 20.283 0.057
BMIadj 0.050 0.258
Preeclampsia 20.002 0.942
Birth weight, SDS 20.017 0.076
24-h systolic BP Sex, pubertal stage FGF21 0.238 20.002 0.970 180
HMW Adn 0.030 0.467
Irisin 20.107 0.481
IGFBP-1 20.034 0.020
SHBG 0.004 0.802
GGT 0.603 0.097
Uric acid 0.210 0.477
BMIadj 0.192 0.031
Preeclampsia 0.127 0.019
Birth weight, SDS 20.062 0.002
Sex and pubertal developmental stage (G/B 1 to 5) were entered as covariates. Skewed variables were logarithmically
or square root–transformed before testing. Standardized b-values are reported. Significant P - values are bold.
r2 is the variance explained by the model.
Abbreviation: SDS, SD score.
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conflicting results could be attributed to the differences in the assays, sample sizes, and
physical activity.
In this study, serum irisin had a positive association with GGT independently of BMIadj,
supporting the relation between irisin and unfavorable metabolic features. Contradictory
results concerning irisin and transaminases have been reported. A negative correlation was
found in obese Chinese adults [51], whereas another study demonstrated increased circu-
lating irisin concentrations in patients with metabolic syndrome and fatty liver disease [52].
To our knowledge only one previous study has investigated the relationship between irisin
and liver enzymes in prepubertal children; no association between irisin and GGT was
found [53].
Li et al. [10] found no significant difference in FGF21 concentrations between the sexes
before the onset of puberty, whereas after that FGF21 levels declined slightly in boys.
However, no effect of sex or puberty have been reported by others [9, 38]. In our study, the
slightly higher FGF21 concentration in girls compared with boys did not reach statistical
significance. HMW Adn was higher in lean Italian prepubertal [42] and 9- to 10-year-old
Japanese girls [43] (without pubertal stage adjustment) compared with boys. In our study of
midpubertal children, girls had higher HMW Adn concentrations than boys. Moreover, in
boys the decrease in HMW Adn was significant from prepubertal or early pubertal stages
toward stage G3, in line with the study of Bo¨ttner et al. [54] that used total Adn mea-
surements. Furthermore, higher irisin levels have been reported in nonobese girls compared
with boys [48], whereas in overweight or obese children or adolescents no sex-related dif-
ference has been detected [15, 16, 48]. Reinehr et al. [16] reported pubertal children to have
significantly higher irisin concentrations compared with prepubertal ones; however, con-
sistent with our findings, pubertal stage [15, 48] or sex [15] had no effect on serum irisin levels
in two other studies.
Both low birth weight and preeclampsia predispose to later cardiovascular morbidity
[18–20]. In the current study, we found no differences in serum FGF21, HMW Adn, or irisin
concentrations or in other measured biochemical parameters between children born SGA,
AGA, or from preeclamptic pregnancies. In addition, in linear regression analyses, birth
weight or maternal preeclampsia had no association with FGF21 or irisin concentrations,
whereas the association between birth weight and HMW Adn was positive. Consistent with
our results, low birth weight was associated with lower HMW Adn and increased insulin
resistance in obese Mexican children [55], and HMW Adn concentrations tended to fall
between 2 and 6 years of age in Catalan SGA-born children with catch-up growth [56].
Although some of the adverse associations between irisin or HMW Adn and some metabolic
parameters tended to be stronger in the SGA than AGA subgroup, a more unfavorable
metabolic profile with regard to low birth weight or exposure to maternal preeclampsia may
be undetectable by the examined parameters.
The strengths of the current study include detailed anthropometric data for the study
subjects at birth and at the age of 12 years and numerous biochemical measurements.
However, there are also some weaknesses. The study age of 12 years is challenging because of
the variable timing in pubertal development.We tried to exclude the possible influence of this
variation on our results by several ways. We adjusted the analyses for the pubertal de-
velopmental stage. Although we controlled for several confounding factors, the one-time
measurement of IS could be a potential limitation in our study. Fasting insulin alone or in
combination with fasting glucose is not an optimal measure for assessing individual IS, but
they may be applicable in studies with well-defined cohorts [57]. We used QUICKI as a
surrogate marker of IS. QUICKI correlates well with the glucose clamp method [58]. Un-
fortunately, we did not have data on other factors influencing IS, such as dietary habits and
the frequency and intensity of exercise. Finally, we measured irisin by using a commercial
ELISA kit with a polyclonal antibody [28]. Although the kit used is considered the best
validated assay for this molecule to date [12], a more accurate assay to detect serum irisin
levels would be desirable.
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In conclusion, in this cohort of 12-year-old healthy children, serum irisin predicted reduced
IS, although the association was weak. Furthermore, the associations between irisin and IS
markers were independent of BMIadj. Serum HMWAdn was a positive predictor for HDL-C,
whereas its associations with IS markers were BMIadj dependent. FGF21 had no in-
dependent contribution to IS or lipid variables in multivariate regression analyses. Some of
the unfavorable associations tended to be stronger in the SGA-born children compared with
those born AGA or from preeclamptic pregnancies. This study supports previous findings on
the effect of low birth weight on adverse metabolic features, which may remain undetectable
by serum irisin, HMW Adn, and FGF21 measurements.
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